Click here to close now.




















Welcome!

News Feed Item

Stand Up To Cancer and the Farrah Fawcett Foundation Announce New HPV Translational Research Team Grant

Research efforts will investigate approaches to develop novel immune therapies for HPV-associated cancers

SAN DIEGO, April 7, 2014 /PRNewswire-USNewswire/ -- Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9. The HPV and Anal Cancer Foundation is supporting the translational research team by making an additional gift to Stand Up To Cancer.

Ellis L. Reinherz, M.D., chief of the Laboratory of Immunobiology and co-director of the Cancer Vaccine Center at Dana-Farber Cancer Institute in Boston, Mass., and Robert I. Haddad, M.D., disease center leader for head and neck oncology at Dana-Farber, will lead the research project titled "Therapeutic CD8 vaccines against conserved E7 HPV epitopes identified by MS."

The SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team Grant will provide $1.2 million in funding over three years for this innovative project. It will focus on patients with HPV-driven cancers (including anal, cervical, and head and neck cancers) who relapse following initial therapy, and for whom few therapeutic options are available, and will provide a novel approach to improving outcomes in this population.

"It's estimated that more than 30,000 HPV-associated cancers occur each year in the United States alone," said Sherry Lansing, SU2C co-founder, founder of the Sherry Lansing Foundation, and chairperson of the Entertainment Industry Foundation Board of Directors. "Research into new therapies that will benefit patients is urgently needed."

"Farrah was committed to the struggle against anal cancer and other forms of cancer," said Alana Stewart, chief executive officer and president of the Farrah Fawcett Foundation. "We are very pleased to continue Farrah's legacy by supporting this important scientific initiative."

"Our mother Paulette passed away in 2010 at the age of 53 after being treated for HPV-related anal cancer with the same, antiquated chemotherapy cocktail first administered to patients in the 1970s," said Justine Almada, executive director of the HPV and Anal Cancer Foundation. "By collaborating with other organizations who share our urgency for a cure, we hope to overcome barriers to therapeutic progress and end the suffering caused by HPV, which causes 5 percent of all cancers worldwide."

Research Team Selection Process and Project Information

The proposals for the SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team Grant were reviewed by a panel of renowned scientists. The committee was co-chaired by Waun Ki Hong, M.D., FACP, D.M.Sc. (hon.), and Lawrence D. Piro, M.D. Hong is division head and professor at The University of Texas MD Anderson Cancer Center, an American Cancer Society professor, and a Samsung distinguished university chair in cancer medicine. Piro is the president and chief executive officer of The Angeles Clinic and Research Institute and professor of clinical medicine at the Keck School of Medicine, University of Southern California.

The process began with a call for ideas by the AACR in September 2013, and eight finalists were invited to submit full proposals. Of the finalists, the committee recommended funding of the Reinherz and Haddad team. The team proposes to develop new vaccines and other immunotherapeutic approaches that stimulate cancer-killing immunity as treatments for patients with HPV-associated cancers, including cancers of the anus, cervix, and head and neck.

"Our project involves the development of vaccines that stimulate specific immune cells to attack HPV-driven cancer cells," said Reinherz. "While current vaccines effectively prevent HPV infection from taking place in unexposed individuals, they are unable to offer protection to those already exposed subjects either at risk of developing a tumor or with an existing cancer. Our vaccine is uniquely designed to attack the cancers even after tumor formation and, importantly, without causing collateral damage to normal tissues. The strategy is to 1) identify the tumor target, 2) activate specific immune cells, and 3) deploy these effectors at the tumor site for selective destruction of the cancer."

The researchers have developed a highly sensitive ion physics method to find "tags," called epitopes, on cancer cells that are entirely specific for the cancer and hence not found on the normal cells in the body. These tags can signal to receptors on a specific type of immune cell, called a cytolytic T lymphocyte (CTL), to attack and kill the cancer once CTLs are programmed by vaccination to do so in the patient's body. One CTL target that the team has already identified has been incorporated into a new therapeutic vaccine that will be tested on patients in a clinical trial as part of this research grant. The team will also use their epitope-identification technology to find other epitopes for the development of additional immunotherapeutic agents. Finally, they will identify the T cell receptors on CTL that provide the best immune response in order to re-engineer the patients' own immune cells in the laboratory for use as a cancer treatment.

"We are focusing in particular on patients with an HPV-driven cancer who have relapsed after their initial therapy," said Haddad. "These patients have few therapeutic options today, and we aim to provide a new and targeted approach to improving outcomes for them. Our expectation is that a therapeutic vaccine would also be less toxic than conventional chemotherapy currently being used in clinical practice."

The project is expected to begin July 2014.

The AACR is responsible for administering the grant and provides ongoing scientific oversight to ensure that progress is being made. Since the launch of SU2C, the AACR has played an integral role as SU2C's Scientific Partner by providing scientific leadership, expert peer review, grants administration, and oversight of progress.

About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry's resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about progress being made in the fight against the disease. As SU2C's scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, Ph.D., conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. All current members of the CFA were co-producers of the 2012 televised special. The late co-founder Laura Ziskin executive produced both the Sept. 5, 2008, and Sept. 10, 2010, broadcasts. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C's president and CEO since 2011.

For more information on Stand Up To Cancer visit http://www.standup2cancer.org.

About the Farrah Fawcett Foundation
The Farrah Fawcett Foundation is a 501(c)(3) nonprofit foundation whose mission is to provide funding for cutting edge cancer research, to support prevention and awareness, and to help those struggling with cancer today through the creation of The Farrah Fawcett Fund for Patient Assistance at various treatment centers around the country.

Actress and Beauty Icon Farrah Fawcett was diagnosed with anal cancer in 2006. She filmed her treatment and journey in this cancer battle in what became 'Farrah's Story,' a documentary that aired to nine million viewers on NBC and was later nominated for an Emmy. Before her death in 2009, she established the Foundation because she 'wanted to make a difference.'

For more information, visit www.thefarrahfawcettfoundation.org.

About the HPV and Anal Cancer Foundation
The HPV and Anal Cancer Foundation is dedicated to empowering anal cancer patients and accelerating prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Specifically, the HPV and Anal Cancer Foundation aims to:

  • Highlight the relevance of human papillomavirus (HPV) in contracting cancer.
  • Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer.
  • Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender neutral vaccination.
  • Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Foundation was incorporated in 2010 after the death of Paulette Crowther by her three children and primary caregivers, Justine, Tristan and Camille Almada. The Foundation has 501(c)(3) non-profit status in the USA and is a registered charity in the United Kingdom.

For more information visit www.analcancerfoundation.org. Follow on Twitter: @HPVAnalCancer or Facebook: www.facebook.com/analcancerfoundation.

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org. Follow the AACR on Twitter: @AACR. Follow the AACR on Facebook: https://www.facebook.com/aacr.org.

SOURCE Stand Up To Cancer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, explained the best practices of continuous testing at high scale, which is rele...
"We have been in business for 21 years and have been building many enterprise solutions, all IT plumbing - server, storage, interconnects," stated Alex Gorbachev, President of Intelligent Systems Services, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
"We specialize in testing. DevOps is all about continuous delivery and accelerating the delivery pipeline and there is no continuous delivery without testing," noted Marc Hornbeek, Sr. Solutions Architect at Spirent Communications, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
How do you securely enable access to your applications in AWS without exposing any attack surfaces? The answer is usually very complicated because application environments morph over time in response to growing requirements from your employee base, your partners and your customers. In his session at @DevOpsSummit, Haseeb Budhani, CEO and Co-founder of Soha, shared five common approaches that DevOps teams follow to secure access to applications deployed in AWS, Azure, etc., and the friction an...
"Alert Logic is a managed security service provider that basically deploys technologies, but we support those technologies with the people and process behind it," stated Stephen Coty, Chief Security Evangelist at Alert Logic, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to tran...
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affect t...